Tuvirumab

Drug Profile

Tuvirumab

Alternative Names: Hepatitis-B-MAb; Human anti-Hep B; OST 577; Ostavir; Ostavir human anti-hepatitis B antibody

Latest Information Update: 22 May 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer PDL BioPharma
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Surface antigen inhibitors; Viral antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 22 May 2001 No-Development-Reported for Hepatitis B in European Union (IV)
  • 22 May 2001 No-Development-Reported for Hepatitis B in Israel (IV)
  • 22 May 2001 No-Development-Reported for Hepatitis B in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top